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Summary
Selenium (Se) is a trace element that plays a criti-
cal role in several processes for human health.
The thyroid is the organ with the highest Se con-
tent per gram of tissue; in thyroid follicular cells,
Se acts as antioxidant by contrasting the produc-
tion of the reactive oxygen species that are gener-
ated during thyroid hormones biosynthesis. In ad-
dition, Se is part of the active site of the deoidinas-
es, the enzymes responsible for thyroid hormones
activation and inactivation.
Herein, the effects of Se supplementation in pa-
tients with thyroid related disorders have been re-
viewed on the basis of the studies published on
this issue.
KEY WORDS: thyroid, selenium, autoimmunity, an-
tioxidant.
Introduction
Selenium (Se) (from the Greek word “Selene” mean-
ing Moon) is an essential trace element, that was dis-
covered in 1817 by the Swedish chemist Jons Jacob
Berzelius (1). Two hundred years later, Se was recog-
nized as a fundamental micronutrient that plays a crit-
ical role in several processes for human health (2-4):
in 1957 Schwarz discovered that traces of Se can pre-
vent liver necrosis in vitamin-E-deficient rats (5) and
some years later, in 1973, Rothruck demonstrated the
biological function of Se as a cofactor of glutathione
peroxidase (GPX) (6). 
Se is the most powerful antioxidant agent present in the
human body (7), it acts as a growth factor, contributes to
the regulation of thyroid hormone biosynthesis, it is a
modulator of cardiovascular health, is important in the
prevention of neurodegenerative diseases and cancer,
and its optimal serum concentrations are required for a
correct immune response and fertility (8, 9).
Se plays an important role in human physiology, and it is
a basic element for many biological processes. Its most
important function is likely to be as a fundamental com-
ponent of the selenoproteins (4). Selenoproteins are a
group of proteins, encoded by at least 25 human genes
(10), presenting in their catalytic site in the amino acid
selenocysteine (Se-Cys). 
The functions of several of the selenoproteins are now
known and approximately half of them have been shown
to protect the cell against the action of reactive oxygen
species (ROS) (10, 11). Selenocysteine-containing pro-
teins influence several biological processes and exhibit
a wide range of functions including free radical catabo-
lism, immune response and carcinogenesis (9, 11). 
A severe Se deficiency is associated with serious en-
demic diseases such as Kashin-Beck disease (an os-
teoarthropathy reported in north-east Asia and Tibet),
Keshan disease (a cardiomyopathy encountered in
some regions of China), but also mixed ematous cre-
tinism as reported in some areas of central Zaire (12).
Se is present in nature in both inorganic and organic
forms (13). Most of the human Se intake originates from
diet, but other sources of Se are the drinking water, the
environmental pollution, and dietary supplementation. In
particular, cereals, organ meats and seafood contains
considerable levels of Se in forms of selenocysteine and
selenomethionine (14).
Se status varies significantly across different popula-
tions and different ethnic groups (4), ranging from se-
vere deficiency to toxic levels (2, 4). The quantity and
the type of Se in foods are not constant all over the
world (15) and the high variability in Se intake is deter-
mined not only by the different Se concentration in the
soil (i.e., volcanic grounds have lower Se content), but
also by other factors that influence the availability of Se
to the food chain or the presence of ions that can com-
plex with Se (2, 4). 
The optimal Se intake is still very debate (16) since it
has been reported that if a low serum Se can contribute
and worsen chronic diseases also Se excesses are as-
sociated with toxicity (17-21). 
Currently, a definition of the optimal Se intake is based
on its role in the modulation of anti-oxidase activity, and
the optimal nutritional level are those necessary to max-
imize the activity of the glutathione peroxidase 1
(GPX1). The optimal intake should bring Se plasmatic
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concentration around 95 µg/L. (range 89-114) (2, 16).
This corresponds to an intake of 75 and 60 µg/day for
men and women, respectively (3, 16). In the US, seleni-
um intake ranges from 60-220 μg/day (21, 22). Se in-
take in Europe is lower than in the US, with large vari-
ability across different countries, ranging from adequate
or marginally adequate intakes in Western and Central
Europe (30-90 μg/day) to low or deficient intakes in
Eastern European countries (7-30 μg/day) (22).
Role of selenium in thyroid physiology
The thyroid gland has the highest content of Se per
mass unit (23) compared to all other endocrine organs
and tissues (4, 10), and the understanding of the funda-
mental role of Se in the thyroid has been increased sig-
nificantly during the past few years (10). 
Several selenoproteins are expressed in thyroid follicu-
lar cells (24-26). Among these, two isoforms of iodothy-
ronine 5’-deiodinase (type1 and type2, DIO1 and DIO2),
which produce active thyroid hormone (4); the thioredox-
in reductase type 1 (27); the selenoprotein P (27); and
three isoforms of glutathione peroxidase, two of which
(GPX1 and GPX4) protect thyroid follicular cells from hy-
drogen peroxide generated by thyroid peroxidase (4),
and the third (GPX3) which is present into the lumen,
where seems to modulate hydrogen peroxide levels
(28).
It is well known that thyroid physiology is closely de-
pendent from the oxidative changes (29): during thyroid
hormone biosynthesis, H2O2 is constantly produced in a
considerable amount, thus exposing the thyroid follicular
cells to high concentrations of H2O2 and ROS (1). The
peroxidative damage is decreased by the action of the
selenoenzymes systems which may be involved in the
regulation of hormone biosynthesis (30). Of note, the
amount of H2O2 produced in thyrocytes is similar to the
amount that can be produced in activated leukocytes
(31), however, while an activated leukocyte’s has a life
of a few hours, adult human thyrocyte’s life spans al-
most seven years (32). Such a long life requires a very
efficient anti-oxidative response process against H2O2
excess and this protective system is represented by se-
lenoproteins with GPX3 in first line (31, 33, 34). Intra thy-
roidal Se concentrations are critical for GPXs activity
and unbalances in this process as consequence of re-
duced Se concentrations can increase the oxidative
stress and produce damages to the thyroid follicular
cells. These damages can determine, to the very end,
cell death and hypothyroidism.
Selenium and autoimmune thyroiditis
Chronic autoimmune Hashimoto’s thyroiditis (HT) is the
most common thyroid disorder and it is the main cause
of acquired hypothyroidism in iodine-sufficient areas
(23). All over the world it has a very high prevalence, af-
fecting about 3% of the population (35). HT is character-
ized by the presence of auto-antibodies directed to the
thyroid epitopes (thyroglobulin and thyroperoxidase),
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which are closely associated with thyroid dysfunction as
consequence of a progressive thyroidal damage and
lymphocytic inflammation (36). 
HT etiology is still unknown but several aspects are in-
volved in its pathogenesis including genetic predisposi-
tion, endogenous and environmental factors, including
Se deficiency. A role of Se deficiency was hypothesized
by the observation of an higher incidence of HT in areas
with severe Se deficiency (37).
Several studies have investigated the possible therapeu-
tic effects of Se administration in patients with HT (12).
In 2002, Gartner et al. conducted a randomized, place-
bo-controlled, blinded trial on 70 female patients in Ger-
many, an area with mild Se and iodine deficiency. The
endpoint of the study was to investigate the effects of a
short-term Se supplementation on the natural corse of
HT. The patients, all under T4 treatment at substitutive
doses, were split in two groups: 36 patients received
200 µg of sodium selenite/day for 3 months, and 34 pa-
tients received placebo. In the supplemented patients,
serum Se levels increased from 0,87 to 1,09 µM and at
the same time anti-TPO antibodies levels dropped by
37% (37).
The same author followed up some of patients for a fur-
ther 6 months with a further decrease of TPO-Ab levels
(38).
In 2003, Duntas et al. reported a 46% drop in thyroid an-
tibodies levels after administration for three months of
200 µg/day of selenomethionine, and a 55,5% drop of
antibodies levels after 6 months of treatment (39). Simi-
lar results have been reported by Mazokopakis in 2007
with the administration for one year of 200 µg/day of se-
lenomethionine (40).
In 2006, Turker et al. compared the efficacy of 100 µg
and 200 µg of selenomethionine supplementation, con-
cluding that a better effect in maximize GPX activities
and suppress autoimmune activity is obtained using the
higher dose (41).
In contrast with the previous studies, Karanikas et al.
found no significant reduction in anti-TPO antibodies af-
ter 3 months of Se supplementation with 200 µg/day of
sodium selenite in a series of Austrian patients with HT
(42).
In 2009, Nacamulli’s study focused mainly on the effect
of a year-long course of Se supplementation in Italian
patients with early-stage HT and a normal thyroid func-
tion or mild hypofunction not receiving substitutive L-T4
therapy. 46 patients were treated with 80 µg/day of sodi-
um selenite for 12 months, while 30 patients were given
no treatment. TPO-Ab or Tg-Ab level decreased signifi-
cantly (30% and 19%, respectively) after 12 months in
the Se-treated group, but not in the control group (43).
More recently, Krysiak and Okopien conducted a ran-
domized clinical trial involving a group of 170 euthyroid
women with recently diagnosed and previously untreat-
ed Hashimoto’s thyroiditis and 41 matched healthy sub-
jects. The primary endpoint was to evaluate the effects
of L-T4, Selenomethionine, or their combination on sev-
eral inflammatory markers (TNF-alpha, IL-1B, IL-6,
MCP-1, IL-2, INF-G, and high sensitivity CRP). The
study demonstrated that L-T4 treatment reduces mono-
cyte release of TNF-a, IL-1b, IL-6, and MCP-1, whereas
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selenomethionine inhibits lymphocyte release of IL-2,
INF-G, TNF-alpha, and plasma CRP levels. The de-
crease in cytokines was even strongest when both
drugs were administrated together (44).
In 2011, Balazs analyzed IFN-g-induced HLA-DR ex-
pression in cultured human thyrocytes at various con-
centrations of sodium selenite. Se has a dose-depend-
ent inhibitory effect on the expression of HLA-DR and
this effect shows an inverse correlation with anti-oxida-
tive capacity, suggesting that this can be one of the
mechanisms associated with the efficacy of Se supple-
mentation in HT (45).
Finally, very recently Anastasilakis et al. described 86
patients with HT and supplemented with 200 µg/day of
Se or placebo. No changes in TSH, FT4, FT3 and TPO-
Ab levels were detected in Se supplemented patients,
while a significant drop in Anti-Tg level (p=0,001) was
observed after a 6 months treatment (46).
Results on efficacy of Se supplementation in HT are still
not univocal, however it seems that Se may improve the
inflammatory activity in patients with HT. Such effect is
more evident in areas of mild Se deficiency, but whether
this effect is specific for HT or may also be effective in
other endocrine autoimmune diseases has yet to be in-
vestigated.
Selenium and post-partum thyroiditis 
Pregnancy is a period characterized by profound alter-
ations in the biochemical parameters of thyroid gland
and thyroid gland, on the other hand, influences the
pregnancy. Thyroid autoimmunity is associated with
an increased risk of miscarriage, women with elevated
TPO-Ab are prone to develop hypothyroxinemia dur-
ing pregnancy and thyroid dysfunction after delivery
(47-49). 
Recurrent abortions have been associated with lower
serum Se levels (50), and during the 3rd trimester of
gestation plasma Se levels drop significantly, returning
to baseline after delivery with a risk, for pregnant
women of Se deficiency. 
Negro et al. reported the effect of Se supplementation
on postpartum thyroid status in TPO-Ab positive preg-
nant women (51). The results indicate that Se supple-
mentation reduced the incidence of post-partum thy-
roiditis and permanent hypothyroidism, and treated
patients showed a significant decrease in the titer of
TPO-Ab in the postpartum period, suggesting that se-
lenium administration is effective in prevention of post-
partum thyroiditis (PPT). Nevertheless, no other stud-
ies so far reported similar results and study replica-
tions are required before confirming the efficacy of Se
supplementation in prevention of PPT (52).
Selenium and Graves’ disease
Graves’ Disease (GD), similarly to HT, is organ-specif-
ic autoimmune-inflammatory disease with a complex
pathogenesis. GD is characterized by lymphocytic in-
filtration of the thyroid gland with the production of an-
tibodies that bind to the thyrotropin receptor, miming
the TSH action (53). The hyperstimulation of the TSH
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receptor causes an increase of thyroid hormone
biosynthesis with H2O2 overproduction. This increases
ROS production and oxidative stress of the thyroid fol-
licular cell (3). It is now a common view that H2O2 is
implicated in the pathogenesis of GD with an imbal-
ance of the antioxidant/oxidant status, as suggested
by several authors (3, 54, 55).
In this view, adequate serum Se levels are fundamental
to contrast the inflammatory processes: low serum Se
levels have been reported in patients with hyperthy-
roidism and Graves’ disease (56) being associated with
the hyperthyroidism, since the administration of antithy-
roid drugs can increase plasma Se (34, 57). The effica-
cy of Se supplementation in GD has been suggested by
Vrca et al., that demonstrated that patients with GD re-
ceiving in addition to methimazole also a supplementa-
tion with and antioxidant mixture of Se, beta-carotene,
and vitamins C and E, led to euthyroidism faster than
patients treated with methimazole alone (58).
Selenium and Graves’ ophthalmopathy
Graves’ orbitopathy (GO) is caused by inflammation in
the orbital connective tissue leading to an enhanced
adipogenesis and overproduction of glycosaminogly-
cans. This causes an increase in orbital volume and fi-
brosis of the extra ocular muscles (59). Oxidative
stress is involved in the pathogenesis of GO (60) as
suggested by the results of studies reporting the effi-
cacy of antioxidant treatment in GO.
In 2000, Bouzas et al. demonstrated that 9 of 11 (82%)
patients treated with oral antioxidants showed an im-
provement of mild to moderately severe Graves’ oph-
thalmopathy while improvement was observed only in
3 of 11 (27%) patients in the untreated group (P < .05)
(61).
A recent study conducted by Marcocci et al. compared
the effects on GO of Se administration compared to an
anti-inflammatory agent, pentoxifylline, and placebo
(62). The results demonstrated that Se treatment was
associated with an improved quality of life, less eye in-
volvement and slower progression of GO, compared
to placebo and to pentoxifylline. In addition, Se sup-
plementation is associated with less side effects. The
study has two limitations: the authors did not meas-
ured the effects on plasma Se concentration of Se ad-
ministration, and the study was conducted in areas of
moderate Se deficiency, which may potentiate the ef-
fects of Se supplementation. 
In addition, no confirmatory studies have been report-
ed, and further trials are necessary to define Se sup-
plementation in the treatment of mild and moderate
GO (60).
Conclusions
In this review the role of the trace element Se was an-
alyzed for its effects on thyroid metabolism and dis-
eases.
Se supplementation seems to produce benefits in the
management of autoimmune thyroid disorders (Tab. 1).
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Se reduces anti-thyroid antibodies levels and im-
proves thyroid morphology at ultrasound in patients
with Hashimoto’s thyroiditis, the administration of Se
in addition to methimazole seems to be associated
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with a faster normalization of hyperthyroidism in pa-
tients with Graves’ disease, and, finally, Se has been
proposed as treatment for mild or moderate Graves’
orbithopathy. 
!
Table 1 - Clinical studies using selenium supplementation in patients with autoimmune thyroid disorders.  
Disease Country Follow-up Study 
Gruop 
Se dose Major outcome Author 
HT 
Germany 3 months 70 
patients 
(F) 
200 µg/day 
(Se selenite) 
Drop in TPO-Ab (-63.3% ) (37) 
Germany 6 months 47 
patients 
(F) 
200 µg/day 
(Se selenite) 
Major decrease in TPO-Ab in 
patients continuing 
supplementation 
(38) 
Greece 6 months 65 
patients  
(56 F/9 
M) 
200 µg/day 
(SeMe) 
Drop in TPO-Ab  
(-46% at 3 months;  
-55,5% at 6 months) 
(39) 
Turkey 9 months 88 
patients 
(F) 
100 or 200 µg/day 
(SeMe) 
Drop in TPO-Ab, major effects 
with 200 µg/day 
(41) 
Greece 6 + 6 months 80 
patients 
(F) 
200 µg/day 
(SeMe) 
Drop in TPO-Ab  
(-20% at 12 months) 
(40) 
Austria 3 months 36 
patients 
(F) 
200 µg/day 
(Se selenite) 
No effect on TPO-Ab (42) 
Italy 12 months 76 
patients  
(65 F/11 
M) 
80 µg/day 
(Se selenite) 
Drop in TPO-Ab (43) 
Poland 6 months 165 
patients 
200 µg/day 
(SeMe) 
Reduction in cytokines 
product?on 
(44) 
Greece 6 months 86 
patients  
(53 F/33 
M) 
200 µg/day 
(SeMe) 
Drop in TPO-Ab  
(not significant) 
(46) 
PPT 
Italy Pregnancy and 
post partum 
232 
patients 
(F) 
200 mcg/day 
(Seme) 
Evaluation of the prevalence 
of PPTD and hypothyroidism 
(51) 
GD 
Croatia 3 months 57 
patients 
Vitamin C and E, 
Beta carotene and 
Selenium 
Attainment of Euthyroidism  (58) 
GO 
Italy 6?+?6 months 159 
patients 
200 mcg/day 
(Selenium) 
Improvement GO (62) 
  HT: Hashimoto!s thyroiditis; PPT: post-partum thyroiditis; GD: Graves! disease; GO: Graves! ophthalmopathy. ©
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However, the story is not completely clarified yet and
additional studies are required to better define doses
and modality of Se supplementation. 
In addition, other limitations in understanding the role
of Se in thyroid autoimmune diseases are associated
with the observation that intrathyroidal Se levels not
directly correlate with serum Se concentrations, and,
in addition, it should be considered that serum Se as-
say are expensive and not recommended in routine
practice. 
Finally, it should be considered that selenium supple-
mentation in subjects with normal selenium levels was
associated with an increased risk of type 2 diabetes,
and an elevated serum selenium levels were linked to
peripheral vascular disease and all-cause mortality in
several population studies (20, 21, 63). Although
these findings need to be confirmed, long-term seleni-
um supplementation should not be viewed as harm-
less and a possibly healthy way to prevent illness, at
least in patients with normal/high Se income.
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